1Tamsma JT, Keizer HJ, Meinders AE. Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited. Ann Oncol,2001;12(10):1353.
2Frank A. Scappaticci Mechanisms and future directions for angiogenesis-based cancer therapies. Journal of Clinical Oncology,2002;20(18):3906.
3Kruger EA, Duray PH, Tsokos MG, et al. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun,2000;268(1):183.
4Hitoshi Yoshiji, Shigeki Kuriyama, Daniel J.et al. The vascular endothelial growth factor receptor KDR/FIK-1 is a major regulator of malignant ascites for mation in the mouse hapatocellular carcinoma model. Hepatology,2001;33(4):841.
5O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell,1997;88(2):277.
6Noriko Yamaguchi, Bela Anand-Apte, Margaret Lee, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J,1999; 18(16):4414.
7Kyoichi Takahashi, Yoshitsugu Saishin, Yumiko Saishin, et al. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J,2003;17(8):896.
8Caisheng Ye, Chong Feng, Shenming Wang, et al. Antiangiogenic and Antitumor Effects of Edostatin on Follicular Thyroid Carcinoma. Endocrinology,2002;143(9):3522.
9Giannoula Klement, Sylvain Baruchel, Janusz Rak, et al. Continuous low-dose theray with vinblastine and VEGF receptor-antibody induces sustained tumor regression without overt toxicity. J Clin Invest,2000;105(8):R15.
